Charles River Laboratories vs Merck KGaA / MilliporeSigma (CDMO): CDMO Comparison
Side-by-side comparison of Charles River Laboratories and Merck KGaA / MilliporeSigma (CDMO) on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- Charles River Laboratories has more FDA inspections on record (7 vs 2) — a deeper regulatory paper trail.
- Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
- Charles River Laboratories has materially broader EMA GMP coverage (9 active certificates vs 2) — stronger EU footprint.
- Charles River Laboratories maintains 2 MHRA / UK GMP certificates; Merck KGaA / MilliporeSigma (CDMO) does not.
- Merck KGaA / MilliporeSigma (CDMO) appears as a manufacturing partner on more matched clinical programs (22 vs 0) — a broader sponsor book.
On a 13-modality CDMO landscape, both Charles River Laboratories and Merck KGaA / MilliporeSigma (CDMO) qualify as Cell Therapy manufacturers; Charles River Laboratories carries the higher composite Signal Score for Cell Therapy programs in this comparison.
What to evaluate for Cell Therapy programs
Both Charles River Laboratories and Merck KGaA / MilliporeSigma (CDMO) qualify as Cell Therapy CDMOs. When choosing between them for Cell Therapy programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.
Autologous vs allogeneic
Autologous needs per-patient scheduling, chain-of-identity, and short turnaround; allogeneic needs scalable batch processing and a master cell bank strategy. Pick a CDMO proven in your model.
Vector & raw materials
Most cell therapies need a viral vector. Confirm whether the CDMO makes vector in-house or coordinates an external supplier, and how that affects timelines.
Closed-system & cleanrooms
Closed, automated processing reduces contamination risk and labor. Ask about cleanroom grade, automation platforms, and parallel-suite capacity.
Cold chain & logistics
Cryopreservation and chain-of-custody are critical for living cells. Evaluate the CDMO's cold-chain and apheresis-to-infusion logistics.
Frequently asked: Charles River Laboratories vs Merck KGaA / MilliporeSigma (CDMO)
Which has the stronger FDA inspection record, Charles River Laboratories or Merck KGaA / MilliporeSigma (CDMO)?
Both Charles River Laboratories and Merck KGaA / MilliporeSigma (CDMO) maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. Charles River Laboratories has 7 FDA inspections on record; Merck KGaA / MilliporeSigma (CDMO) has 2.
How do Charles River Laboratories and Merck KGaA / MilliporeSigma (CDMO) compare on European GMP coverage?
Charles River Laboratories holds 9 active EMA GMP certificates and 2 MHRA / UK certificates. Merck KGaA / MilliporeSigma (CDMO) holds 2 active EMA GMP certificates and 0 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
Which is more active in clinical-stage manufacturing — Charles River Laboratories or Merck KGaA / MilliporeSigma (CDMO)?
Charles River Laboratories is matched to 0 ClinicalTrials.gov records as a manufacturing partner; Merck KGaA / MilliporeSigma (CDMO) is matched to 22. Higher counts indicate broader sponsor exposure but say nothing about approved-product track record — pair this number with each CDMO's profile page for context.
Which is better for Cell Therapy manufacturing — Charles River Laboratories or Merck KGaA / MilliporeSigma (CDMO)?
Both Charles River Laboratories and Merck KGaA / MilliporeSigma (CDMO) are tagged as Cell Therapy CDMOs in our directory, so both are credible options for Cell Therapy programs. The most important differentiator for Cell Therapy selection is typically autologous vs allogeneic: Autologous needs per-patient scheduling, chain-of-identity, and short turnaround; allogeneic needs scalable batch processing and a master cell bank strategy. Pick a CDMO proven in your model. Review each CDMO's profile and inspection record before shortlisting.
What does the Signal Score gap mean in practice?
Charles River Laboratories carries a Signal Score of 92/100 and Merck KGaA / MilliporeSigma (CDMO) carries 82/100 — a small lead for Charles River Laboratories. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →